Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia

References

• Kovacic JC, Castellano JM, Fuster V. Cardiovascular defense challenges at the basic, clinical, and population levels. Ann N Y Acad Sci. 2012;1254:1–6.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.
   PubMed Web of Science ®Google Scholar
• Graham IM, Catapano AL, Wong ND. Current guidelines on prevention with a focus on dyslipidemias. Cardiovasc Diagn Ther. 2017;7:S4–S10.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Patel J, Martin SS, Banach M. Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opin Pharmacother. 2016;17:1497–1507.
   PubMed Web of Science ®Google Scholar
• Ewang-Emukowhate M, Wierzbicki AS. Lipid-lowering agents. J Cardiovasc Pharmacol Ther. 2013;18:401–411.
   PubMed Web of Science ®Google Scholar
• Shaughnessy AF. Niacin does not decrease mortality in patients with coronary artery disease or low HDL. Am Fam Physician. 2017;96:129.
   PubMed Web of Science ®Google Scholar
• Jakob T, Nordmann AJ, Schandelmaier S, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016;11:CD009753.
   PubMedGoogle Scholar
• Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol. 2016;67:353–361.
   PubMed Web of Science ®Google Scholar
• Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther. 2003;25:2352–2387.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44:467–494.
   PubMed Web of Science ®Google Scholar
• Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265:568–580.
   PubMed Web of Science ®Google Scholar
• Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1084–1091.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–2192.
   PubMed Web of Science ®Google Scholar
• Nozue T, Michishita I, Mizuguchi I. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb. 2010;17:37–44.
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New Engl J Med. 2008;358:1431–1443.
   PubMed Web of Science ®Google Scholar
• Wang J, Ai XB, Wang F, et al. Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Int Angiol. 2017;36:467–473.
   PubMed Web of Science ®Google Scholar
• Thongtang N, Lin J, Schaefer EJ, et al. Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients. Atherosclerosis. 2012;225:388–396.
   PubMed Web of Science ®Google Scholar
• Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–2134.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009;103:1694–1702.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251–261.
   PubMed Web of Science ®Google Scholar
• Davignon J, Dubuc G, Seidah NG. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep. 2010;12:308–315.
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272.
   PubMed Web of Science ®Google Scholar
• Pucci G, Cicero AF, Borghi C, et al. Emerging biologic therapies for hypercholesterolaemia. Expert Opin Biol Ther. 2017;17:1077–1087.
   PubMed Web of Science ®Google Scholar
• Cicero AF, Tartagni E, Ertek S. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Expert Opin Drug Saf. 2014;13:1023–1030.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1499.
   PubMed Web of Science ®Google Scholar
• Squizzato A, Suter MB, Nerone M, et al. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Intern Emerg Med. 2017. [Epub ahead of print]. DOI:10.1007/s11739-017-1708-7.
   PubMed Web of Science ®Google Scholar
• Amgen Inc. EMDAC meeting briefing document (evolocumab): background information for Endocrinologic and Metabolic Drugs Advisory Commitee. 2015. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM450072.pdf
   Google Scholar
• Smith JP. Food and drug administration center for drug evaluation and research. Briefing document: praluent (alirocumab) injection. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 2015. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drug/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM449865.pdf
   Google Scholar
• Colletti A, Derosa G, Cicero AF. Retargeting the management of hypercholesterolemia - focus on evolocumab. Ther Clin Risk Manag. 2016;12:1365–1376.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 Aug 24;377(8):787–788.
   Web of Science ®Google Scholar
• Toth PP, Descamps O2, Genest J, et al. Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. Circulation. 2017;135:1819–1831.
   PubMed Web of Science ®Google Scholar
• Kasssner U, Schlabs T, Rosada A, et al. Lipoprotein(a)-An independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl. 2015;18:263–267.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Watts GF, Robinson JG, et al. Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the phase 3 ODYSSEY program). Am J Cardiol. 2017;119:40–46.
   PubMed Web of Science ®Google Scholar
• Orringer CE, Jacobson TA, Saseen JJ, et al. Update on the use of PCSK9 inhibitors in adults: recommendations from an expert panel of the national lipid association. J Clin Lipidol. 2017;11:880–890.
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41–51.
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383:60–68.
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430–1440.
   PubMed Web of Science ®Google Scholar
• Page MM, Hooper AJ, Burnett JR. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors? Expert Opin Pharmacother. 2016;17(2):275–281.
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Besseling J, Shah S, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo controlled, phase 3 study. Lancet. 2015;385:2153–2161.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Shirakawa M, Kikuchi M, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia. Atherosclerosis. 2013;230:52–60.
   PubMed Web of Science ®Google Scholar
• van der Tuin SJ, Kühnast S, Berbée JF, et al. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res. 2015;56(11):2085–2093.
   PubMed Web of Science ®Google Scholar
• Borghi C, Cicero AF. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia. Expert Opin Drug Metab Toxicol. 2017;13:205–209.
   PubMed Web of Science ®Google Scholar
• Kumar S, Tan EY, Hartmann G, et al. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos. 2010;38:474–483.
   PubMed Web of Science ®Google Scholar
• Bloomfield D, Carlson GL, Sapre A, et al. Efficacy, safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy, coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352–360.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415.
   PubMed Web of Science ®Google Scholar
• Landray MJ, Reveal Collaborative Group, Bowman L, et al. Randomized evaluation of the effects of anacetrapib through lipid-modification (REVEAL)-a large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: trial design, recruitment, and baseline characteristics. Am Heart J. 2017;187:182–190.
   PubMed Web of Science ®Google Scholar
• HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1217.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Nov 05]. Available from: http://www.pharmatimes.com/news/msd_pulls_plug_on_cholesterol_drug_anacetrapib_1208152
   Google Scholar
• Walsh MT, Di Leo E, Okur I, et al. Structure-function analyses of microsomal triglyceride transfer protein missense mutations in abetalipoproteinemia and hypobetalipoproteinemia subjects. Biochim Biophys Acta. 2016;1861:1623–1633.
   PubMed Web of Science ®Google Scholar
• Berberich AJ, Hegele RA. Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2017;18:1261–1268.
   PubMed Web of Science ®Google Scholar
• Taubel J, Sumeray M, Lorch U, et al. Pharmacokinetics and pharmacodynamics of lomitapide in Japanese subjects. J Atheroscler Thromb. 2016;23:606–620.
   PubMed Web of Science ®Google Scholar
• Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–46.
   PubMed Web of Science ®Google Scholar
• Harada-Shiba M, Ikewaki K, Nohara A, et al. Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2017;24:402–411.
   PubMed Web of Science ®Google Scholar
• Geary RS, Baker BF, Crooke ST. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro((R))): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet. 2015;54:133–146.
   PubMed Web of Science ®Google Scholar
• Panta R, Dahal K, Kunwar S. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials. J Clin Lipidol. 2015;9:217–225.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377:222–232.
   PubMed Web of Science ®Google Scholar
• Brandt TA, Lee RG, Digenio A, et al. ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers. Atheroscler Suppl. 2015;241:e30–1.
   Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al. Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid lowering therapies. J Clin Lipidol. 2016;10:715.
   Google Scholar
• Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472–1483.
   PubMed Web of Science ®Google Scholar
• Bernelot Moens SJ, van Capelleveen JC, Stroes ES. Inhibition of ApoCIII: the next PCSK9? Curr Opin Lipidol. 2014;25:418–422.
   PubMed Web of Science ®Google Scholar
• Rotllan N, Price N, Pati P, et al. microRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis. 2016;246:352–360.
   PubMed Web of Science ®Google Scholar
• Reiner Ž, De Backer G, Fras Z, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries–findings from the EUROASPIRE IV survey. Atherosclerosis. 1016;246:243–250.
   Google Scholar
• Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341–350.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Fogacci F, Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food Funct. 2017;8:2076–2088.
   PubMed Web of Science ®Google Scholar
• Chang Y, Robidoux J. Dyslipidemia management update. Curr Opin Pharmacol. 2017;33:47–55.
   PubMed Web of Science ®Google Scholar
• Han L, Shen WJ, Bittner S, et al. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α. Future Cardiol. 2017;13:259–278.
   PubMedGoogle Scholar
• Carroll C, Tappenden P, Rafia R, et al. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2017;35:537–547.
   PubMed Web of Science ®Google Scholar
• Baum SJ, Toth PP, Underberg JA, et al. PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers. Clin Cardiol. 2017;40:243–254.
   PubMed Web of Science ®Google Scholar
• Gaspoz JM, Kennedy JW, Orav EJ, et al. Cost-effectiveness of prescription recommendations for cholesterol-lowering drugs: a survey of a representative sample of American cardiologists. J Am Coll Cardiol. 1996;27:1232–1237.
   PubMed Web of Science ®Google Scholar
• Reckless JP. Cost implications of lipid-lowering treatments. Pharmacoeconomics. 1994;6:310–323.
   PubMed Web of Science ®Google Scholar
• Waldeyer C, Seiffert M, Staebe N, et al. Lipid management after first diagnosis of coronary artery disease: contemporary results from an observational cohort study. Clin Ther. 2017. pii: S0149-2918(17)31005-6. [Epub ahead of print]. 10.1016/j.clinthera.2017.10.005
   PubMedGoogle Scholar
• Bohn B, Schöfl C, Zimmer V, et al. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis. Cardiovasc Diabetol. 2016;15:72.
   PubMed Web of Science ®Google Scholar